Skip to content

Advertisement

  • Meeting abstract
  • Open Access

Metformin treatment improves vascular function in rats with neonatal streptozotocin-induced type 2 diabetes

  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Critical Care20037 (Suppl 3) :P127

https://doi.org/10.1186/cc2323

  • Published:

Keywords

  • Histamine
  • Metformin
  • Bradykinin
  • Streptozotocin
  • Platelet Activate Factor

Objective

To verify the influence of the antihyperglycaemic agent metformin on the microvascular reactivity to inflammatory and noninflammatory mediators in type 2 diabetes.

Methods

Type 2 diabetes was induced by streptozotocin injection (160 mg/kg, intraperitoneally) in neonate (2-day-old) Wistar rats. The animals were treated with metformin (300 mg/kg) per os during 15 days. Using intravital microscopy, the changes in arteriolar diameters were determined in chloral hydrate (450 mg/kg, subcutaneously) control rats, diabetic (D) rats and diabetic treated with metformin (D + M) anesthetized rats, before and after topical application of the endothelium-dependent vasodilator noninflammatory mediator agent acetylcholine (24 nmol), the endothelium-independent vasodilator agent sodium nitroprusside (58 nmol), the endothelium-dependent vasodilator and inflammatory mediator agents bradykinin (42 pmol), histamine (4.1 nmol) and platelet activating factor (60 pmol), and the vasoconstrictor agent norepinephrine (4.7 pmol, 14.1 pmol and 47 pmol).

Results

The effects of acetylcholine, and 4.7 pmol and 47 pmol norepinephrine in D + M rats were not different from those in D rats (Table 1). On the other hand, metformin improved sodium nitroprusside, bradykinin, histamine and platelet activating factor-induced relaxation diminished in D rats. It also improved norepinephrine-induced vasoconstriction, enhanced in D rats to control levels (Table 1).
Table 1

Arteriolar diameters (% alteration)

Rats

Norepinephrine (4.7 pmol)

Norepinephrine (14.1 pmol)

Acetylcholine (24 nmol)

Sodium nitroprusside (58 nmol)

Bradykinin (42 pmol)

Histamine (4.1 nmol)

Platelet activating factor (60 pmol)

Control

1.41 ± 0.46

7.25 ± 0.98

5.70 ± 0.60

6.16 ± 0.51

6.82 ± 0.29

6.14 ± 0.4

6.88 ± 0.7

 

(n = 12)

(n = 12)

(n = 13)

(n = 7)

(n = 12)

(n = 14)

(n = 8)

Diabetic

4.07 ± 0.53

69.29 ± 11.34*

1.17 ± 0.50

2.57 ± 0.68*

1.51 ± 0.23*

2.1 ± 0.37

2.25 ± 0.66*

 

(n = 11)

(n = 13)

(n = 8)

(n = 7)

(n = 14)

(n = 8)

(n = 8)

Diabetic + metformin

6.05 ± 0.91

14.89 ± 3.33

1.91 ± 0.82

5.39 ± 0.56

6.88 ± 0.56

7.9 ± 0.71†‡

5.7 ± 0.9

 

(n = 9)

(n = 11)

(n = 10)

(n = 7)

(n = 14)

(n = 10)

(n = 8)

*P < 0.05 in comparison with control rats and diabetic + metformin rats. P < 0.05 in comparison with control rats. P < 0.05 in comparison with diabetic rats.

Conclusion

Type 2 diabetes seemed to affect the vascular responses to inflammatory and noninflammatory mediators. Metformin corrects such alterations in the diabetic rats.

Declarations

Acknowledgement

Financial support from FAPESP.

Authors’ Affiliations

(1)
Department of Pharmacology, ICB-USP, CEP, Cidade Universitária, Av Prof. Lineu Prestes 1524, São Paulo, 05508-9000, Brazil

Copyright

© BioMed Central Ltd 2003

Advertisement